JPWO2021142002A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021142002A5 JPWO2021142002A5 JP2022535120A JP2022535120A JPWO2021142002A5 JP WO2021142002 A5 JPWO2021142002 A5 JP WO2021142002A5 JP 2022535120 A JP2022535120 A JP 2022535120A JP 2022535120 A JP2022535120 A JP 2022535120A JP WO2021142002 A5 JPWO2021142002 A5 JP WO2021142002A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- set forth
- sequence set
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 437
- 239000000427 antigen Substances 0.000 claims description 113
- 102000036639 antigens Human genes 0.000 claims description 113
- 108091007433 antigens Proteins 0.000 claims description 113
- 210000004027 cell Anatomy 0.000 claims description 45
- 206010028980 Neoplasm Diseases 0.000 claims description 36
- 102000039446 nucleic acids Human genes 0.000 claims description 28
- 108020004707 nucleic acids Proteins 0.000 claims description 28
- 150000007523 nucleic acids Chemical class 0.000 claims description 28
- 210000000822 natural killer cell Anatomy 0.000 claims description 21
- 101000716063 Homo sapiens C-C chemokine receptor type 8 Proteins 0.000 claims description 19
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims description 18
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims description 17
- 230000001939 inductive effect Effects 0.000 claims description 17
- 108091008874 T cell receptors Proteins 0.000 claims description 16
- 229940127121 immunoconjugate Drugs 0.000 claims description 14
- 239000008194 pharmaceutical composition Substances 0.000 claims description 12
- 102100036305 C-C chemokine receptor type 8 Human genes 0.000 claims description 11
- 102000048031 human CCR8 Human genes 0.000 claims description 8
- 230000001404 mediated effect Effects 0.000 claims description 8
- 230000001105 regulatory effect Effects 0.000 claims description 8
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 claims description 6
- 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 claims description 6
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 claims description 6
- 230000003213 activating effect Effects 0.000 claims description 5
- 150000001413 amino acids Chemical class 0.000 claims description 5
- 230000000779 depleting effect Effects 0.000 claims description 5
- 239000000611 antibody drug conjugate Substances 0.000 claims description 4
- 229940049595 antibody-drug conjugate Drugs 0.000 claims description 4
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 claims description 3
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 claims description 3
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 claims description 3
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 3
- 230000003828 downregulation Effects 0.000 claims description 3
- 230000003827 upregulation Effects 0.000 claims description 3
- 241000282567 Macaca fascicularis Species 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 230000002708 enhancing effect Effects 0.000 claims description 2
- 239000012634 fragment Substances 0.000 claims description 2
- 230000028993 immune response Effects 0.000 claims description 2
- 101100112922 Candida albicans CDR3 gene Proteins 0.000 claims 73
- 239000000203 mixture Substances 0.000 claims 2
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 claims 2
- 238000004458 analytical method Methods 0.000 claims 1
- 238000000159 protein binding assay Methods 0.000 claims 1
- 238000000034 method Methods 0.000 description 51
- 239000013598 vector Substances 0.000 description 26
- 239000002246 antineoplastic agent Substances 0.000 description 20
- 239000003112 inhibitor Substances 0.000 description 11
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 6
- 229960002633 ramucirumab Drugs 0.000 description 4
- 201000009030 Carcinoma Diseases 0.000 description 3
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 description 3
- 101710083479 Hepatitis A virus cellular receptor 2 homolog Proteins 0.000 description 3
- 206010025323 Lymphomas Diseases 0.000 description 3
- 230000006051 NK cell activation Effects 0.000 description 3
- 239000012271 PD-L1 inhibitor Substances 0.000 description 3
- 229940126547 T-cell immunoglobulin mucin-3 Drugs 0.000 description 3
- 239000000556 agonist Substances 0.000 description 3
- 229950002916 avelumab Drugs 0.000 description 3
- 208000032839 leukemia Diseases 0.000 description 3
- 229960003301 nivolumab Drugs 0.000 description 3
- 229940121656 pd-l1 inhibitor Drugs 0.000 description 3
- 229960002621 pembrolizumab Drugs 0.000 description 3
- SPMVMDHWKHCIDT-UHFFFAOYSA-N 1-[2-chloro-4-[(6,7-dimethoxy-4-quinolinyl)oxy]phenyl]-3-(5-methyl-3-isoxazolyl)urea Chemical compound C=12C=C(OC)C(OC)=CC2=NC=CC=1OC(C=C1Cl)=CC=C1NC(=O)NC=1C=C(C)ON=1 SPMVMDHWKHCIDT-UHFFFAOYSA-N 0.000 description 2
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 description 2
- 206010004146 Basal cell carcinoma Diseases 0.000 description 2
- 206010005003 Bladder cancer Diseases 0.000 description 2
- 206010008342 Cervix carcinoma Diseases 0.000 description 2
- 208000006332 Choriocarcinoma Diseases 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 2
- HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 description 2
- 208000017604 Hodgkin disease Diseases 0.000 description 2
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 2
- 101001102797 Homo sapiens Transmembrane protein PVRIG Proteins 0.000 description 2
- 239000002147 L01XE04 - Sunitinib Substances 0.000 description 2
- 239000005511 L01XE05 - Sorafenib Substances 0.000 description 2
- 239000003798 L01XE11 - Pazopanib Substances 0.000 description 2
- 229940125563 LAG3 inhibitor Drugs 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- 206010029260 Neuroblastoma Diseases 0.000 description 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 2
- 206010033128 Ovarian cancer Diseases 0.000 description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 description 2
- 229940124060 PD-1 antagonist Drugs 0.000 description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 2
- 201000000582 Retinoblastoma Diseases 0.000 description 2
- 206010039491 Sarcoma Diseases 0.000 description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 description 2
- CBPNZQVSJQDFBE-FUXHJELOSA-N Temsirolimus Chemical compound C1C[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 CBPNZQVSJQDFBE-FUXHJELOSA-N 0.000 description 2
- 208000024313 Testicular Neoplasms Diseases 0.000 description 2
- 206010057644 Testis cancer Diseases 0.000 description 2
- 102100039630 Transmembrane protein PVRIG Human genes 0.000 description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 2
- 208000002495 Uterine Neoplasms Diseases 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 208000009956 adenocarcinoma Diseases 0.000 description 2
- 229960003982 apatinib Drugs 0.000 description 2
- 229960003852 atezolizumab Drugs 0.000 description 2
- RITAVMQDGBJQJZ-FMIVXFBMSA-N axitinib Chemical compound CNC(=O)C1=CC=CC=C1SC1=CC=C(C(\C=C\C=2N=CC=CC=2)=NN2)C2=C1 RITAVMQDGBJQJZ-FMIVXFBMSA-N 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 201000010881 cervical cancer Diseases 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229950009791 durvalumab Drugs 0.000 description 2
- 201000004101 esophageal cancer Diseases 0.000 description 2
- 206010017758 gastric cancer Diseases 0.000 description 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 2
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 2
- WOSKHXYHFSIKNG-UHFFFAOYSA-N lenvatinib Chemical compound C=12C=C(C(N)=O)C(OC)=CC2=NC=CC=1OC(C=C1Cl)=CC=C1NC(=O)NC1CC1 WOSKHXYHFSIKNG-UHFFFAOYSA-N 0.000 description 2
- 201000007270 liver cancer Diseases 0.000 description 2
- 208000014018 liver neoplasm Diseases 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- 208000020816 lung neoplasm Diseases 0.000 description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- WPEWQEMJFLWMLV-UHFFFAOYSA-N n-[4-(1-cyanocyclopentyl)phenyl]-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide Chemical compound C=1C=CN=C(NCC=2C=CN=CC=2)C=1C(=O)NC(C=C1)=CC=C1C1(C#N)CCCC1 WPEWQEMJFLWMLV-UHFFFAOYSA-N 0.000 description 2
- 201000008968 osteosarcoma Diseases 0.000 description 2
- 201000002528 pancreatic cancer Diseases 0.000 description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 description 2
- CUIHSIWYWATEQL-UHFFFAOYSA-N pazopanib Chemical compound C1=CC2=C(C)N(C)N=C2C=C1N(C)C(N=1)=CC=NC=1NC1=CC=C(C)C(S(N)(=O)=O)=C1 CUIHSIWYWATEQL-UHFFFAOYSA-N 0.000 description 2
- 201000009410 rhabdomyosarcoma Diseases 0.000 description 2
- 229950007213 spartalizumab Drugs 0.000 description 2
- 201000011549 stomach cancer Diseases 0.000 description 2
- 201000003120 testicular cancer Diseases 0.000 description 2
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 description 2
- 239000005483 tyrosine kinase inhibitor Substances 0.000 description 2
- 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 description 2
- 201000005112 urinary bladder cancer Diseases 0.000 description 2
- 206010046766 uterine cancer Diseases 0.000 description 2
- KMIOJWCYOHBUJS-HAKPAVFJSA-N vorolanib Chemical compound C1N(C(=O)N(C)C)CC[C@@H]1NC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C KMIOJWCYOHBUJS-HAKPAVFJSA-N 0.000 description 2
- YPBKTZBXSBLTDK-PKNBQFBNSA-N (3e)-3-[(3-bromo-4-fluoroanilino)-nitrosomethylidene]-4-[2-(sulfamoylamino)ethylamino]-1,2,5-oxadiazole Chemical compound NS(=O)(=O)NCCNC1=NON\C1=C(N=O)/NC1=CC=C(F)C(Br)=C1 YPBKTZBXSBLTDK-PKNBQFBNSA-N 0.000 description 1
- XYDNMOZJKOGZLS-NSHDSACASA-N 3-[(1s)-1-imidazo[1,2-a]pyridin-6-ylethyl]-5-(1-methylpyrazol-4-yl)triazolo[4,5-b]pyrazine Chemical compound N1=C2N([C@H](C3=CN4C=CN=C4C=C3)C)N=NC2=NC=C1C=1C=NN(C)C=1 XYDNMOZJKOGZLS-NSHDSACASA-N 0.000 description 1
- MLDQJTXFUGDVEO-FIBGUPNXSA-N 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-n-(trideuteriomethyl)pyridine-2-carboxamide Chemical compound C1=NC(C(=O)NC([2H])([2H])[2H])=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-FIBGUPNXSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 108010075480 ADI PEG20 Proteins 0.000 description 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
- 201000003076 Angiosarcoma Diseases 0.000 description 1
- 206010003571 Astrocytoma Diseases 0.000 description 1
- 208000036170 B-Cell Marginal Zone Lymphoma Diseases 0.000 description 1
- 229940125565 BMS-986016 Drugs 0.000 description 1
- 208000005440 Basal Cell Neoplasms Diseases 0.000 description 1
- 206010005949 Bone cancer Diseases 0.000 description 1
- 208000018084 Bone neoplasm Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 208000011691 Burkitt lymphomas Diseases 0.000 description 1
- 102100021943 C-C motif chemokine 2 Human genes 0.000 description 1
- 206010007953 Central nervous system lymphoma Diseases 0.000 description 1
- 208000005243 Chondrosarcoma Diseases 0.000 description 1
- 201000009047 Chordoma Diseases 0.000 description 1
- 208000002699 Digestive System Neoplasms Diseases 0.000 description 1
- 206010014733 Endometrial cancer Diseases 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- 206010014967 Ependymoma Diseases 0.000 description 1
- 208000031637 Erythroblastic Acute Leukemia Diseases 0.000 description 1
- 208000036566 Erythroleukaemia Diseases 0.000 description 1
- 208000006168 Ewing Sarcoma Diseases 0.000 description 1
- 201000008808 Fibrosarcoma Diseases 0.000 description 1
- 208000032612 Glial tumor Diseases 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- 208000001258 Hemangiosarcoma Diseases 0.000 description 1
- 101000897480 Homo sapiens C-C motif chemokine 2 Proteins 0.000 description 1
- 101000831007 Homo sapiens T-cell immunoreceptor with Ig and ITIM domains Proteins 0.000 description 1
- 208000007766 Kaposi sarcoma Diseases 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- 239000002138 L01XE21 - Regorafenib Substances 0.000 description 1
- 239000002176 L01XE26 - Cabozantinib Substances 0.000 description 1
- 102000017578 LAG3 Human genes 0.000 description 1
- UCEQXRCJXIVODC-PMACEKPBSA-N LSM-1131 Chemical compound C1CCC2=CC=CC3=C2N1C=C3[C@@H]1C(=O)NC(=O)[C@H]1C1=CNC2=CC=CC=C12 UCEQXRCJXIVODC-PMACEKPBSA-N 0.000 description 1
- 101150030213 Lag3 gene Proteins 0.000 description 1
- 206010023825 Laryngeal cancer Diseases 0.000 description 1
- 208000018142 Leiomyosarcoma Diseases 0.000 description 1
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 description 1
- 208000007054 Medullary Carcinoma Diseases 0.000 description 1
- 208000000172 Medulloblastoma Diseases 0.000 description 1
- 206010027406 Mesothelioma Diseases 0.000 description 1
- 208000003445 Mouth Neoplasms Diseases 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
- 108700031757 NKTR-214 Proteins 0.000 description 1
- 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 description 1
- 206010061306 Nasopharyngeal cancer Diseases 0.000 description 1
- 208000034176 Neoplasms, Germ Cell and Embryonal Diseases 0.000 description 1
- 201000010133 Oligodendroglioma Diseases 0.000 description 1
- 208000007641 Pinealoma Diseases 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 208000006265 Renal cell carcinoma Diseases 0.000 description 1
- 229940044665 STING agonist Drugs 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 206010041067 Small cell lung cancer Diseases 0.000 description 1
- 102100024834 T-cell immunoreceptor with Ig and ITIM domains Human genes 0.000 description 1
- 229940125555 TIGIT inhibitor Drugs 0.000 description 1
- 229940125567 TSR-033 Drugs 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- 208000014070 Vestibular schwannoma Diseases 0.000 description 1
- 208000008383 Wilms tumor Diseases 0.000 description 1
- 208000004064 acoustic neuroma Diseases 0.000 description 1
- 208000017733 acquired polycythemia vera Diseases 0.000 description 1
- 208000021841 acute erythroid leukemia Diseases 0.000 description 1
- 229940042992 afinitor Drugs 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 229940120638 avastin Drugs 0.000 description 1
- 229960003005 axitinib Drugs 0.000 description 1
- 229940121413 bempegaldesleukin Drugs 0.000 description 1
- 229960000397 bevacizumab Drugs 0.000 description 1
- 201000009036 biliary tract cancer Diseases 0.000 description 1
- 208000020790 biliary tract neoplasm Diseases 0.000 description 1
- 229950003054 binimetinib Drugs 0.000 description 1
- ACWZRVQXLIRSDF-UHFFFAOYSA-N binimetinib Chemical compound OCCONC(=O)C=1C=C2N(C)C=NC2=C(F)C=1NC1=CC=C(Br)C=C1F ACWZRVQXLIRSDF-UHFFFAOYSA-N 0.000 description 1
- 210000000133 brain stem Anatomy 0.000 description 1
- 208000003362 bronchogenic carcinoma Diseases 0.000 description 1
- 229940036033 cabometyx Drugs 0.000 description 1
- 229960001292 cabozantinib Drugs 0.000 description 1
- ONIQOQHATWINJY-UHFFFAOYSA-N cabozantinib Chemical compound C=12C=C(OC)C(OC)=CC2=NC=CC=1OC(C=C1)=CC=C1NC(=O)C1(C(=O)NC=2C=CC(F)=CC=2)CC1 ONIQOQHATWINJY-UHFFFAOYSA-N 0.000 description 1
- HFCFMRYTXDINDK-WNQIDUERSA-N cabozantinib malate Chemical compound OC(=O)[C@@H](O)CC(O)=O.C=12C=C(OC)C(OC)=CC2=NC=CC=1OC(C=C1)=CC=C1NC(=O)C1(C(=O)NC=2C=CC(F)=CC=2)CC1 HFCFMRYTXDINDK-WNQIDUERSA-N 0.000 description 1
- 229950007712 camrelizumab Drugs 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 208000006990 cholangiocarcinoma Diseases 0.000 description 1
- 208000024207 chronic leukemia Diseases 0.000 description 1
- 201000002660 colon sarcoma Diseases 0.000 description 1
- 239000000562 conjugate Substances 0.000 description 1
- 201000010918 connective tissue cancer Diseases 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 208000002445 cystadenocarcinoma Diseases 0.000 description 1
- 208000024558 digestive system cancer Diseases 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 201000002246 embryonal cancer Diseases 0.000 description 1
- 229950006370 epacadostat Drugs 0.000 description 1
- 208000010932 epithelial neoplasm Diseases 0.000 description 1
- 229960005167 everolimus Drugs 0.000 description 1
- 208000024519 eye neoplasm Diseases 0.000 description 1
- 229940125449 fotivda Drugs 0.000 description 1
- 201000010231 gastrointestinal system cancer Diseases 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 208000025750 heavy chain disease Diseases 0.000 description 1
- 201000002222 hemangioblastoma Diseases 0.000 description 1
- 229940121569 ieramilimab Drugs 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 229940005319 inlyta Drugs 0.000 description 1
- 208000020082 intraepithelial neoplasia Diseases 0.000 description 1
- 229960005386 ipilimumab Drugs 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 206010023841 laryngeal neoplasm Diseases 0.000 description 1
- 229960003784 lenvatinib Drugs 0.000 description 1
- 229940064847 lenvima Drugs 0.000 description 1
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 description 1
- 206010024627 liposarcoma Diseases 0.000 description 1
- 208000012804 lymphangiosarcoma Diseases 0.000 description 1
- 208000016847 malignant urinary system neoplasm Diseases 0.000 description 1
- 201000007924 marginal zone B-cell lymphoma Diseases 0.000 description 1
- 208000021937 marginal zone lymphoma Diseases 0.000 description 1
- 208000023356 medullary thyroid gland carcinoma Diseases 0.000 description 1
- 206010027191 meningioma Diseases 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 229940124303 multikinase inhibitor Drugs 0.000 description 1
- 208000001611 myxosarcoma Diseases 0.000 description 1
- LBWFXVZLPYTWQI-IPOVEDGCSA-N n-[2-(diethylamino)ethyl]-5-[(z)-(5-fluoro-2-oxo-1h-indol-3-ylidene)methyl]-2,4-dimethyl-1h-pyrrole-3-carboxamide;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C LBWFXVZLPYTWQI-IPOVEDGCSA-N 0.000 description 1
- FYJROXRIVQPKRY-UHFFFAOYSA-N n-[4-(1-cyanocyclopentyl)phenyl]-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide;methanesulfonic acid Chemical compound CS(O)(=O)=O.C=1C=CN=C(NCC=2C=CN=CC=2)C=1C(=O)NC(C=C1)=CC=C1C1(C#N)CCCC1 FYJROXRIVQPKRY-UHFFFAOYSA-N 0.000 description 1
- 201000008026 nephroblastoma Diseases 0.000 description 1
- 229940080607 nexavar Drugs 0.000 description 1
- 229960004378 nintedanib Drugs 0.000 description 1
- XZXHXSATPCNXJR-ZIADKAODSA-N nintedanib Chemical compound O=C1NC2=CC(C(=O)OC)=CC=C2\C1=C(C=1C=CC=CC=1)\NC(C=C1)=CC=C1N(C)C(=O)CN1CCN(C)CC1 XZXHXSATPCNXJR-ZIADKAODSA-N 0.000 description 1
- 229950011068 niraparib Drugs 0.000 description 1
- PCHKPVIQAHNQLW-CQSZACIVSA-N niraparib Chemical compound N1=C2C(C(=O)N)=CC=CC2=CN1C(C=C1)=CC=C1[C@@H]1CCCNC1 PCHKPVIQAHNQLW-CQSZACIVSA-N 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 201000008106 ocular cancer Diseases 0.000 description 1
- 230000002188 osteogenic effect Effects 0.000 description 1
- 208000004019 papillary adenocarcinoma Diseases 0.000 description 1
- 201000010198 papillary carcinoma Diseases 0.000 description 1
- 229960000639 pazopanib Drugs 0.000 description 1
- 210000003800 pharynx Anatomy 0.000 description 1
- 229950010773 pidilizumab Drugs 0.000 description 1
- 208000024724 pineal body neoplasm Diseases 0.000 description 1
- 201000004123 pineal gland cancer Diseases 0.000 description 1
- 238000011518 platinum-based chemotherapy Methods 0.000 description 1
- 208000037244 polycythemia vera Diseases 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 208000016800 primary central nervous system lymphoma Diseases 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 206010038038 rectal cancer Diseases 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 229960004836 regorafenib Drugs 0.000 description 1
- FNHKPVJBJVTLMP-UHFFFAOYSA-N regorafenib Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=C(F)C(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 FNHKPVJBJVTLMP-UHFFFAOYSA-N 0.000 description 1
- 210000003289 regulatory T cell Anatomy 0.000 description 1
- 201000007048 respiratory system cancer Diseases 0.000 description 1
- 229950003500 savolitinib Drugs 0.000 description 1
- 201000008407 sebaceous adenocarcinoma Diseases 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 210000003625 skull Anatomy 0.000 description 1
- 208000000587 small cell lung carcinoma Diseases 0.000 description 1
- 150000003384 small molecules Chemical group 0.000 description 1
- 229960003787 sorafenib Drugs 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 229960001796 sunitinib Drugs 0.000 description 1
- WINHZLLDWRZWRT-ATVHPVEESA-N sunitinib Chemical compound CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C WINHZLLDWRZWRT-ATVHPVEESA-N 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 229940034785 sutent Drugs 0.000 description 1
- 201000010965 sweat gland carcinoma Diseases 0.000 description 1
- 206010042863 synovial sarcoma Diseases 0.000 description 1
- 229940066453 tecentriq Drugs 0.000 description 1
- 229960000235 temsirolimus Drugs 0.000 description 1
- QFJCIRLUMZQUOT-UHFFFAOYSA-N temsirolimus Natural products C1CC(O)C(OC)CC1CC(C)C1OC(=O)C2CCCCN2C(=O)C(=O)C(O)(O2)C(C)CCC2CC(OC)C(C)=CC=CC=CC(C)CC(C)C(=O)C(OC)C(O)C(C)=CC(C)C(=O)C1 QFJCIRLUMZQUOT-UHFFFAOYSA-N 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 229950007123 tislelizumab Drugs 0.000 description 1
- 229960000940 tivozanib Drugs 0.000 description 1
- 229940100411 torisel Drugs 0.000 description 1
- 229950007217 tremelimumab Drugs 0.000 description 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
- 201000004435 urinary system cancer Diseases 0.000 description 1
- 229950009827 vorolanib Drugs 0.000 description 1
- 229940069559 votrient Drugs 0.000 description 1
- 229940055760 yervoy Drugs 0.000 description 1
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024147372A JP2024170466A (ja) | 2020-01-06 | 2024-08-29 | 抗ｃｃｒ８抗体及びその使用 |
| JP2025154025A JP2025178338A (ja) | 2020-01-06 | 2025-09-17 | 抗ｃｃｒ８抗体及びその使用 |
| JP2025154024A JP2025178337A (ja) | 2020-01-06 | 2025-09-17 | 抗ｃｃｒ８抗体及びその使用 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062957758P | 2020-01-06 | 2020-01-06 | |
| US62/957,758 | 2020-01-06 | ||
| US202062985152P | 2020-03-04 | 2020-03-04 | |
| US62/985,152 | 2020-03-04 | ||
| US202063198803P | 2020-11-13 | 2020-11-13 | |
| US63/198,803 | 2020-11-13 | ||
| PCT/US2021/012329 WO2021142002A1 (en) | 2020-01-06 | 2021-01-06 | Anti-ccr8 antibodies and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024147372A Division JP2024170466A (ja) | 2020-01-06 | 2024-08-29 | 抗ｃｃｒ８抗体及びその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023509323A JP2023509323A (ja) | 2023-03-08 |
| JPWO2021142002A5 true JPWO2021142002A5 (enExample) | 2024-01-04 |
| JP7606518B2 JP7606518B2 (ja) | 2024-12-25 |
Family
ID=74418541
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022535120A Active JP7606518B2 (ja) | 2020-01-06 | 2021-01-06 | 抗ｃｃｒ８抗体及びその使用 |
| JP2024147372A Pending JP2024170466A (ja) | 2020-01-06 | 2024-08-29 | 抗ｃｃｒ８抗体及びその使用 |
| JP2025154024A Pending JP2025178337A (ja) | 2020-01-06 | 2025-09-17 | 抗ｃｃｒ８抗体及びその使用 |
| JP2025154025A Pending JP2025178338A (ja) | 2020-01-06 | 2025-09-17 | 抗ｃｃｒ８抗体及びその使用 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024147372A Pending JP2024170466A (ja) | 2020-01-06 | 2024-08-29 | 抗ｃｃｒ８抗体及びその使用 |
| JP2025154024A Pending JP2025178337A (ja) | 2020-01-06 | 2025-09-17 | 抗ｃｃｒ８抗体及びその使用 |
| JP2025154025A Pending JP2025178338A (ja) | 2020-01-06 | 2025-09-17 | 抗ｃｃｒ８抗体及びその使用 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US11859000B2 (enExample) |
| EP (1) | EP4087607A1 (enExample) |
| JP (4) | JP7606518B2 (enExample) |
| KR (2) | KR20250095745A (enExample) |
| CN (1) | CN114929278A (enExample) |
| AR (1) | AR132614A2 (enExample) |
| AU (2) | AU2021205877B2 (enExample) |
| CA (1) | CA3160204A1 (enExample) |
| IL (2) | IL321341A (enExample) |
| MX (3) | MX2022008341A (enExample) |
| TW (1) | TWI845803B (enExample) |
| WO (1) | WO2021142002A1 (enExample) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI845803B (zh) | 2020-01-06 | 2024-06-21 | 美商法西尼克斯股份有限公司 | 抗ｃｃｒ８抗體及其用途 |
| US20230063151A1 (en) * | 2020-01-29 | 2023-03-02 | The Wistar Institute Of Anatomy And Biology | Cd40-l blockade to enhance synthetic antibody therapy |
| TW202216771A (zh) * | 2020-06-26 | 2022-05-01 | 德商拜耳廠股份有限公司 | 用於治療應用之ccr8抗體 |
| MX2023004349A (es) | 2020-10-16 | 2023-08-22 | Lanova Medicines Ltd | Anticuerpos monoclonales anti-ccr8 y sus usos. |
| EP4317439A4 (en) | 2021-03-31 | 2025-04-02 | Shionogi & Co., Ltd. | Chimeric antigen receptor that recognizes CCR8 as an antigen |
| CR20230581A (es) * | 2021-06-04 | 2024-02-13 | Amgen Inc | Anticuerpos anti-CCR8 y usos de los mismos |
| HUE069018T2 (hu) * | 2021-07-27 | 2025-02-28 | Abbvie Inc | Anti-CCR8 antitestek |
| US20250019451A1 (en) * | 2021-08-20 | 2025-01-16 | Hifibio, Inc. | Anti-ccr8 antibodies and uses thereof |
| US20250368744A1 (en) * | 2021-12-23 | 2025-12-04 | Concept To Medicine Biotech Co., Ltd. | Anti-ccr8 antibodies and uses thereof |
| CN116789820A (zh) * | 2022-03-18 | 2023-09-22 | 北京天诺健成医药科技有限公司 | 一种新型免疫调节剂的开发和应用 |
| WO2023206350A1 (en) * | 2022-04-29 | 2023-11-02 | Analytical Biosciences Shanghai Limited | Anti-ccr8 antibodies and uses thereof |
| KR20250018387A (ko) | 2022-05-24 | 2025-02-05 | 브리스톨-마이어스 스큅 컴퍼니 | 인간 ccr8에 결합하는 항체 |
| CA3258344A1 (en) | 2022-06-07 | 2023-12-14 | Actinium Pharmaceuticals Inc | CHELETARIANS AND BIFUNCTIONAL CONJUGATES |
| WO2024008110A1 (zh) * | 2022-07-07 | 2024-01-11 | 四川思柏沃生物技术有限公司 | 抗ccr8抗体及其应用 |
| AU2023319869A1 (en) * | 2022-08-04 | 2025-02-20 | Beone Medicines I Gmbh | Anti-ccr8 antibodies and methods of use |
| AU2023325323A1 (en) * | 2022-08-19 | 2025-03-27 | Fibrogen, Inc. | Anti-ccr8 antibodies and uses thereof |
| WO2024062082A1 (en) | 2022-09-21 | 2024-03-28 | Domain Therapeutics | Anti-ccr8 monoclonal antibodies and their therapeutic use |
| WO2024062019A1 (en) | 2022-09-21 | 2024-03-28 | Synabs | Anti-ccr8 antibodies and uses thereof |
| WO2024062072A2 (en) | 2022-09-21 | 2024-03-28 | Domain Therapeutics | Anti-ccr8 monoclonal antibodies and their therapeutic use |
| WO2024062076A1 (en) | 2022-09-21 | 2024-03-28 | Domain Therapeutics | Anti-ccr8 monoclonal antibodies and their therapeutic use |
| KR20250099234A (ko) * | 2022-11-04 | 2025-07-01 | 바이오세우스 인크. | 항-ccr8 항체 및 이의 용도 |
| WO2024109657A1 (zh) * | 2022-11-22 | 2024-05-30 | 上海宏成药业有限公司 | 抗ccr8抗体及其用途 |
| TW202423987A (zh) * | 2022-12-07 | 2024-06-16 | 大陸商廣東菲鵬製藥股份有限公司 | 抗ccr8抗體及其應用 |
| TW202436351A (zh) | 2023-02-06 | 2024-09-16 | 德商拜耳廠股份有限公司 | Ccr8抗體及dgk抑制劑之組合 |
| WO2024240224A1 (zh) * | 2023-05-23 | 2024-11-28 | 再鼎医药(上海)有限公司 | 包含抗ccr8抗体的制剂及其用途 |
| WO2024255753A1 (zh) * | 2023-06-12 | 2024-12-19 | 南京蓬勃生物科技有限公司 | 结合人ccr8的抗体及其用途 |
| WO2024255467A1 (en) * | 2023-06-16 | 2024-12-19 | Genor Biopharma Co., Ltd. | Anti-ccr8 antibody and anti-ccr8/ctla4 bispecific antibody |
| CN117285627B (zh) * | 2023-09-06 | 2024-06-14 | 百济神州(上海)生物科技有限公司 | 抗ccr8抗体及其用途 |
| WO2025061993A1 (en) | 2023-09-21 | 2025-03-27 | Domain Therapeutics | Anti-ccr8 monoclonal antibodies and their therapeutic use |
| WO2025061994A1 (en) | 2023-09-21 | 2025-03-27 | Domain Therapeutics | Anti-ccr8 monoclonal antibodies and their therapeutic use |
| WO2025076288A1 (en) | 2023-10-06 | 2025-04-10 | Amgen Inc. | Combination therapy for cancer treatment |
| WO2025113643A1 (en) | 2023-12-01 | 2025-06-05 | Gilead Sciences Inc. | Anti-fap-light fusion protein and use thereof |
| WO2025145207A1 (en) | 2023-12-29 | 2025-07-03 | Bristol-Myers Squibb Company | Combination therapy of kras inhibitor and treg-depleting agent |
| WO2025186043A1 (en) | 2024-03-06 | 2025-09-12 | Bayer Aktiengesellschaft | Pharmaceutical formulation for anti-ccr8 antibodies |
| WO2025191147A1 (en) | 2024-03-14 | 2025-09-18 | Synabs | Anti-ccr8 antibodies and uses thereof |
| WO2025226603A1 (en) | 2024-04-22 | 2025-10-30 | Surface Oncology, LLC | Methods for treating cancer using anti-ccr8 antibodies |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
Family Cites Families (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4263428A (en) | 1978-03-24 | 1981-04-21 | The Regents Of The University Of California | Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same |
| IE52535B1 (en) | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
| DE3374837D1 (en) | 1982-02-17 | 1988-01-21 | Ciba Geigy Ag | Lipids in the aqueous phase |
| HUT35524A (en) | 1983-08-02 | 1985-07-29 | Hoechst Ag | Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance |
| EP0143949B1 (en) | 1983-11-01 | 1988-10-12 | TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION | Pharmaceutical composition containing urokinase |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| AU600575B2 (en) | 1987-03-18 | 1990-08-16 | Sb2, Inc. | Altered antibodies |
| EP1997891A1 (en) | 1988-09-02 | 2008-12-03 | Dyax Corporation | Generation and selection of recombinant varied binding proteins |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| US5780225A (en) | 1990-01-12 | 1998-07-14 | Stratagene | Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules |
| WO1991010737A1 (en) | 1990-01-11 | 1991-07-25 | Molecular Affinities Corporation | Production of antibodies using gene libraries |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| US5698426A (en) | 1990-09-28 | 1997-12-16 | Ixsys, Incorporated | Surface expression libraries of heteromeric receptors |
| WO1992009690A2 (en) | 1990-12-03 | 1992-06-11 | Genentech, Inc. | Enrichment method for variant proteins with altered binding properties |
| US6565841B1 (en) | 1991-03-15 | 2003-05-20 | Amgen, Inc. | Pulmonary administration of granulocyte colony stimulating factor |
| DE69233750D1 (de) | 1991-04-10 | 2009-01-02 | Scripps Research Inst | Bibliotheken heterodimerer Rezeptoren mittels Phagemiden |
| EP0590058B1 (en) | 1991-06-14 | 2003-11-26 | Genentech, Inc. | HUMANIZED Heregulin ANTIBODy |
| ATE408012T1 (de) | 1991-12-02 | 2008-09-15 | Medical Res Council | Herstellung von autoantikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken |
| US5470582A (en) | 1992-02-07 | 1995-11-28 | Syntex (U.S.A.) Inc. | Controlled delivery of pharmaceuticals from preformed porous polymeric microparticles |
| US5714350A (en) | 1992-03-09 | 1998-02-03 | Protein Design Labs, Inc. | Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region |
| US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| US6005079A (en) | 1992-08-21 | 1999-12-21 | Vrije Universiteit Brussels | Immunoglobulins devoid of light chains |
| EP0656946B2 (en) | 1992-08-21 | 2010-03-31 | Vrije Universiteit Brussel | Immunoglobulins devoid of light chains |
| DE69427974T2 (de) | 1993-04-29 | 2001-12-06 | Unilever N.V., Rotterdam | Herstellung von antikörpern oder funktionstüchtig gemachten teilen davon, abgeleitet von schweren ketten von immunglobulinen von camelidae |
| WO1994029351A2 (en) | 1993-06-16 | 1994-12-22 | Celltech Limited | Antibodies |
| WO1995015982A2 (en) | 1993-12-08 | 1995-06-15 | Genzyme Corporation | Process for generating specific antibodies |
| DK1231268T3 (da) | 1994-01-31 | 2005-11-21 | Univ Boston | Polyklonale antistofbiblioteker |
| US5516637A (en) | 1994-06-10 | 1996-05-14 | Dade International Inc. | Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| CA2229043C (en) | 1995-08-18 | 2016-06-07 | Morphosys Gesellschaft Fur Proteinoptimierung Mbh | Protein/(poly)peptide libraries |
| JP2978435B2 (ja) | 1996-01-24 | 1999-11-15 | チッソ株式会社 | アクリロキシプロピルシランの製造方法 |
| AU3117697A (en) | 1996-05-06 | 1997-11-26 | Uab Research Foundation, The | Radiolabeled fusion toxins for cancer therapy |
| DE69937291T2 (de) | 1998-04-02 | 2008-07-10 | Genentech, Inc., South San Francisco | Antikörpervarianten und fragmente davon |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| US6995259B1 (en) | 1998-10-23 | 2006-02-07 | Sirna Therapeutics, Inc. | Method for the chemical synthesis of oligonucleotides |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| BR0008758A (pt) | 1999-01-15 | 2001-12-04 | Genentech Inc | Variantes de polipeptìdeos parentais com funçãoefetora alterada, polipeptìdeos, composição ácidonucleico isolado, vetor, célula hospedeira,método para produzir uma variante depolipeptìdeo, método para o tratamento de umadesordem em mamìferos e método para produziruma região fc variante |
| US7361740B2 (en) | 2002-10-15 | 2008-04-22 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
| PT1572744E (pt) | 2002-12-16 | 2010-09-07 | Genentech Inc | Variantes de imunoglobulina e utilizações destas |
| BR122019012028B1 (pt) | 2004-04-13 | 2023-09-26 | F. Hoffmann-La Roche Ag | Anticorpos anti-p-selectina, molécula de ácido nucléico, vetor, e composição |
| TWI380996B (zh) | 2004-09-17 | 2013-01-01 | Hoffmann La Roche | 抗ｏｘ４０ｌ抗體 |
| TWI323734B (en) | 2005-08-19 | 2010-04-21 | Abbott Lab | Dual variable domain immunoglobulin and uses thereof |
| US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| WO2007044756A2 (en) | 2005-10-11 | 2007-04-19 | Icos Corporation | Monoclonal antibodies recognizing human ccr8 |
| WO2013131010A2 (en) | 2012-03-02 | 2013-09-06 | Icahn School Of Medicine At Mount Sinai | Function of chemokine receptor ccr8 in melanoma metastasis |
| GB2519786A (en) | 2013-10-30 | 2015-05-06 | Sergej Michailovic Kiprijanov | Multivalent antigen-binding protein molecules |
| ES2923641T3 (es) | 2013-12-30 | 2022-09-29 | Epimab Biotherapeutics Inc | Inmunoglobulina con Fabs en tándem y usos de la misma |
| US9300829B2 (en) | 2014-04-04 | 2016-03-29 | Canon Kabushiki Kaisha | Image reading apparatus and correction method thereof |
| WO2018112032A1 (en) * | 2016-12-13 | 2018-06-21 | President And Fellows Of Harvard College | Methods and compositions for targeting tumor-infiltrating tregs using inhibitors of ccr8 and tnfrsf8 |
| EP3431105B1 (en) * | 2017-03-29 | 2020-01-01 | Shionogi&Co., Ltd. | Medicinal composition for treating cancer |
| WO2019157098A1 (en) * | 2018-02-06 | 2019-08-15 | Advaxis, Inc. | Compositions comprising a recombinant listeria strain and an anti-ccr8 antibody and methods of use |
| TWI845803B (zh) | 2020-01-06 | 2024-06-21 | 美商法西尼克斯股份有限公司 | 抗ｃｃｒ８抗體及其用途 |
-
2021
- 2021-01-06 TW TW110100492A patent/TWI845803B/zh active
- 2021-01-06 EP EP21702556.8A patent/EP4087607A1/en active Pending
- 2021-01-06 MX MX2022008341A patent/MX2022008341A/es unknown
- 2021-01-06 WO PCT/US2021/012329 patent/WO2021142002A1/en not_active Ceased
- 2021-01-06 US US17/142,862 patent/US11859000B2/en active Active
- 2021-01-06 CN CN202180007992.9A patent/CN114929278A/zh active Pending
- 2021-01-06 CA CA3160204A patent/CA3160204A1/en active Pending
- 2021-01-06 AU AU2021205877A patent/AU2021205877B2/en active Active
- 2021-01-06 KR KR1020257019586A patent/KR20250095745A/ko active Pending
- 2021-01-06 JP JP2022535120A patent/JP7606518B2/ja active Active
- 2021-01-06 IL IL321341A patent/IL321341A/en unknown
- 2021-01-06 KR KR1020227020514A patent/KR102821932B1/ko active Active
-
2022
- 2022-06-27 IL IL294330A patent/IL294330B2/en unknown
- 2022-07-05 MX MX2024002158A patent/MX2024002158A/es unknown
- 2022-07-05 MX MX2024002152A patent/MX2024002152A/es unknown
-
2024
- 2024-05-06 AR ARP240101148A patent/AR132614A2/es unknown
- 2024-08-23 AU AU2024216306A patent/AU2024216306A1/en active Pending
- 2024-08-29 JP JP2024147372A patent/JP2024170466A/ja active Pending
-
2025
- 2025-09-17 JP JP2025154024A patent/JP2025178337A/ja active Pending
- 2025-09-17 JP JP2025154025A patent/JP2025178338A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2021142002A5 (enExample) | ||
| JP2024170466A5 (enExample) | ||
| TWI791519B (zh) | 針對淋巴細胞活化基因-3（lag-3）之抗體藥劑及其用途 | |
| AU2018226298B2 (en) | Anti-LAG-3 antibodies and uses thereof | |
| US10519236B2 (en) | Antibodies specific to delta 1 chain of T cell receptor | |
| TWI840386B (zh) | 抗間皮素抗體 | |
| TWI774137B (zh) | 針對cd3和bcma的抗體和自其製備的雙特異性結合蛋白 | |
| JP2020501531A5 (enExample) | ||
| JP6608698B2 (ja) | Ｐ２ｘ７受容体アンタゴニスト及びアゴニスト | |
| IL293244A (en) | Agonist antibodies against icos and their uses | |
| JP7712925B2 (ja) | 腫瘍治療のための二重特異性融合タンパク質と抗Ｈｅｒ２抗体の組合せ | |
| KR20210062026A (ko) | 항-tnfrsf9 항체 및 그의 용도 | |
| US12383631B2 (en) | Immune antigen specific IL-18 immunocytokines and uses thereof | |
| JP2021503911A (ja) | 抗ｏｘ４０抗体及びその用途 | |
| CN110172099A (zh) | 抗lag-3人源化单克隆抗体分子，抗原结合片段及其医药用途 | |
| US20240342246A1 (en) | Interleukin-12 variants and methods of use | |
| CN114641498A (zh) | 结合amhrii的抗体药物缀合物及其在治疗癌症中的用途 | |
| JP2025172885A (ja) | 腫瘍治療のための二重特異性融合タンパク質 | |
| TWI865617B (zh) | 抗原結合蛋白 | |
| KR20190107719A (ko) | 세리티닙 및 항-pd-1 항체 분자의 조합물에 대한 투여 일정 | |
| CN111973739A (zh) | 抗pd-l1单克隆抗体治疗癌症的用途 | |
| CN118139884A (zh) | 人源化抗clec-1a抗体和其抗原结合片段及其模拟物 | |
| KR20230004635A (ko) | Csf-1r에 의해 조절되는 질병을 치료하기 위한 투여 요법 | |
| WO2024208354A1 (en) | Antibody drug conjugates | |
| RU2835316C1 (ru) | Режим введения доз для лечения заболевания, модулируемого csf-1r |